Findings underscore the ongoing value to the myeloma scientific community of the MMRF’s landmark molecular and clinical data and translational research programs

研究结果强调了MMRF具有里程碑意义的分子和临床数据以及转化研究项目对骨髓瘤科学界的持续价值

Norwalk, Conn., September 27, 2023 — The Multiple Myeloma Research Foundation (MMRF) today announced that findings from three studies based on analyses of its CoMMpass℠ and CureCloud℠ datasets will be featured in an oral abstract and poster presentations at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece, September 27-30, 2023.

康涅狄格州诺沃克（Norwalk），2023年9月27日-多发性骨髓瘤研究基金会（MMRF）今天宣布，三项研究的结果基于其CoMMpass分析℠ 和CureCloud℠ 数据集将在2023年9月27日至30日在希腊雅典举行的第20届国际骨髓瘤学会（IMS）年会上以口头摘要和海报形式展示。

Topics include:.

主题包括：。

Multi-omic analysis of multiple myeloma subtypes based on samples from the MMRF CoMMpass Study

基于MMRF CoMMpass研究样本的多发性骨髓瘤亚型的多组学分析

Single-cell profiling in rapidly progressing multiple myeloma patients enrolled in the CoMMpass Study as part of the MMRF Immune Atlas research program

作为MMRF免疫图谱研究计划的一部分，参加CoMMpass研究的快速进展多发性骨髓瘤患者的单细胞分析

A real-world longitudinal investigation of patient treatments and outcomes, including Patient Reported Outcome (PRO) surveys from the MMRF CureCloud Research Initiative

对患者治疗和结果进行现实世界的纵向调查，包括来自MMRF CureCloud研究计划的患者报告结果（PRO）调查

Additionally, data from the CoMMpass Study are cited in 24 posters and four education sessions, demonstrating its enduring value in driving new advancements across multiple myeloma research. With its inclusion in more than 300 publications and abstracts, CoMMpass represents the largest longitudinal genomic dataset in multiple myeloma and has led to groundbreaking discoveries that have transformed how researchers understand the biology of the disease..

此外，来自CoMMpass研究的数据被引用在24个海报和4个教育会议上，展示了其在推动多发性骨髓瘤研究新进展方面的持久价值。CoMMpass包含在300多篇出版物和摘要中，代表了多发性骨髓瘤中最大的纵向基因组数据集，并导致了突破性的发现，这些发现改变了研究人员对疾病生物学的理解方式。。

To develop a more comprehensive picture of myeloma disease biology, the MMRF is expanding the CoMMpass dataset with immune data from its Immune Atlas research program. In addition, the MMRF’s CureCloud, a first-of-its-kind registry, has amassed clinical, genomic, immune, and patient-reported outcome (PRO) data across more than 1,000 participants.

为了更全面地了解骨髓瘤疾病生物学，MMRF正在使用其免疫图谱研究计划的免疫数据扩展CoMMpass数据集。此外，MMRF的CureCloud是首个同类注册机构，已经在1000多名参与者中积累了临床，基因组，免疫和患者报告的结果（PRO）数据。

The MMRF makes the datasets from CoMMpass, Immune Atlas, and CureCloud available to researchers, facilitating the development of optimal treatments for all myeloma patients..

MMRF使CoMMpass，Immune Atlas和CureCloud的数据集可供研究人员使用，促进所有骨髓瘤患者的最佳治疗方案的开发。。

'Our consistent investment in the generation, analysis and sharing of new data with researchers worldwide accelerates the pace of scientific discovery to benefit each and every myeloma patient,” said George Mulligan, Ph.D., Chief Scientific Officer of the MMRF and co-author on two of the studies to be shared at IMS.

MMRF首席科学官兼合着者George Mulligan博士说：“我们与世界各地的研究人员在生成，分析和共享新数据方面的持续投资加快了科学发现的步伐，使每个骨髓瘤患者受益。”其中两项研究将在IMS共享。

“I am optimistic that, with greater understanding of this disease biology and continued collaboration in the research community, multiple myeloma patients will have improved therapeutic options now and also steadily increasing approaches to rational and potentially curative treatment strategies.”.

“我乐观地认为，随着对这种疾病生物学的更多了解以及研究界的持续合作，多发性骨髓瘤患者现在将有更好的治疗选择，并且还将稳步增加理性和潜在治愈性治疗策略的方法。”。

About the MMRF data to be shared at IMS 2023

关于将在IMS 2023共享的MMRF数据

Friday, September 29, 2023

星期五，2023年9月29日

Poster Session 3, 1:15 PM – 2:15 PM EEST

海报会议3:15 PM-2:15 PM EEST

Multi-omic analysis of multiple myeloma subtypes reveals epigenetic programs of high-risk disease

多发性骨髓瘤亚型的多组学分析揭示了高危疾病的表观遗传程序

Identifying the biology of high-risk multiple myeloma is critical to improving outcomes. Current markers imperfectly predict high-risk disease and there are limited data that integrate genetic, epigenetic, and transcriptional information with outcomes. DNA methylation data was generated based on 415 samples from the MMRF CoMMpass study and identified distinct epigenetic programs of high-risk disease..

确定高危多发性骨髓瘤的生物学特征对于改善预后至关重要。目前的标记不能完全预测高风险疾病，并且将遗传，表观遗传和转录信息与结果相结合的数据有限。基于来自MMRF CoMMpass研究的415个样品产生DNA甲基化数据，并鉴定了高风险疾病的不同表观遗传程序。。

Friday, September 29, 2023

星期五，2023年9月29日

Poster Session 3, 1:15 PM – 2:15 PM EEST

海报会议3:15 PM-2:15 PM EEST

Single-Cell Profiling Reveals Inflammaging-associated Dysregulations in Rapidly Progressing Multiple Myeloma Patients

单细胞分析揭示快速进展的多发性骨髓瘤患者中炎症相关的失调

Modern therapies for multiple myeloma rely on the immune system for their effectiveness and positive outcomes. Dysregulation in the immune compartment can promote disease progress and hamper the effectiveness of immune-based therapies. In this study for the characterization of bone marrow and its association with the kinetics of multiple myeloma, researchers performed Single Cell Profiling on bone marrow samples from the MMRF CoMMpass cohort..

多发性骨髓瘤的现代疗法依赖于免疫系统的有效性和积极的结果。免疫隔室中的失调可促进疾病进展并妨碍基于免疫的疗法的有效性。在这项关于骨髓表征及其与多发性骨髓瘤动力学相关性的研究中，研究人员对来自MMRF CoMMpass队列的骨髓样本进行了单细胞分析。。

Friday, September 29, 2023

星期五，2023年9月29日

Poster Session 3, 1:15 PM – 2:15 PM EEST

海报会议3:15 PM-2:15 PM EEST

The MMRF CureCloud research study: a real-world longitudinal investigation of patient treatments and outcomes, including Patient Reported Outcome (PRO) surveys

MMRF CureCloud研究：对患者治疗和结果的真实世界纵向调查，包括患者报告结果（PRO）调查

CureCloud integrates molecular and real-world evidence data, including electronic health records (EHR) and PROs collected at six-month intervals. This poster is an analysis of the baseline PRO data. In general, patients were able to answer the PRO instruments electronically. The results indicate that younger and less socioeconomically advantaged patients experienced higher financial toxicity..

CureCloud集成了分子和现实世界的证据数据，包括电子健康记录（EHR）和每隔六个月收集的PRO。这张海报是对基线PRO数据的分析。一般来说，患者能够以电子方式回答PRO仪器。结果表明，年轻和社会经济优势较低的患者经历了较高的经济毒性。。

About the Multiple Myeloma Research Foundation (MMRF)

关于多发性骨髓瘤研究基金会

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives.

多发性骨髓瘤研究基金会（MMRF）是世界上最大的非营利组织，专注于加速a 治愈 对于每个多发性骨髓瘤患者。我们推动下一代疗法的开发和实施，利用数据确定最佳和更个性化的治疗方法，并为骨髓瘤患者和更广泛的社区提供信息和资源，以延长他们的生命。

Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients.

我们使命的核心是我们致力于推进健康公平，以便所有骨髓瘤患者都能从我们追求的科学和临床进步中受益。自成立以来，MMRF已投入超过5亿美元用于研究，开展了近100项临床试验，并帮助将15+FDA批准的疗法推向市场，这使骨髓瘤患者的预期寿命增加了三倍。

To learn more, visit www.themmrf.org..

要了解更多信息，请访问www.themmrf.org。。